Dr. Darrell Orlyn Ricke (born 1959)
https://www.ll.mit.edu/news/2018-mit-lincoln-laboratory-technical-awards
full : 517157-044D.jpg
517157-044D-crop.jpg
Wikipedia 🌐 NONE
ASSOCIATIONS
Darrell O. Ricke, PhD
Dr. Darrell Ricke has extensive experience in molecular biology, genomics, functional genomics, bioinformatics, computational biology, programming, and software engineering. Dr. Ricke has worked extensively in these areas in applications of understanding the mechanisms of human diseases, biology discovery, data integration, and data mining. His current research focuses on biomedical research with applications in designing medical countermeasures to viral, biotoxins, and bacterial pathogens, epigenetics, transcriptomics, metagenomics, and disease mutation analysis.
https://www.actox.org/am/am2021/plenary.asp
1996 (Feb 05) - The Albuquerque Tribune :
https://www.newspapers.com/image/785191470/?terms=%22darrell%20ricke%22&match=1
1996-02-05-the-albuquerque-tribune-pg-a2
1996-02-05-the-albuquerque-tribune-pg-a2-clip-genetics
Darrell Orlyn Ricke
(Darrel O Rick)
BIRTHDATE
3/23/1959 (64yrs)
LOCATION
Winchester, MA
https://www.whitepages.com/name/Darrell-Orlyn-Ricke/Winchester-MA/PN3VDalOY9g?is_best_match=true
2023-04-13-whitepages-com-darrell-orlyn-ricke-winchester-ma.pdf
2018 MIT award
https://www.ll.mit.edu/news/2018-mit-lincoln-laboratory-technical-awards
Dr. Darrell O. Ricke, Tara L. Boettcher, Philip D. Fremont-Smith, Adam M. Michaleas, Dr. Martha S. Petrovick, Dr. Eric D. Schwoebel, and James G. Watkins
For the invention of Advanced DNA Forensics System, which is associated with 21 technology disclosures that were filed between 2013 and 2018.
The Advanced DNA Forensics System incorporates ultrafast computational methods for searching DNA databases and advanced forensics for complex DNA mixture analysis. This invention enables the rapid comparison of DNA samples from individuals and mixtures against a large DNA profile database and provides improved statistical confidence measures. The DNA forensics can be performed on a laptop for multiple military and criminal justice applications, has been transitioned to FBI Quantico R&D, and will continue to have an important and expanding impact on national security.
2019 (Sep) presentation
https://ieee-hpec.org/2019/2019Program/program_htm_files/04-66-2019IEEEHPECIdPrismtalk.pdf
04-66-2019IEEEHPECIdPrismtalk.pdf
Models for COVID-19 Early Cardiac Pathology Following SARS-CoV-2 Infection Maurice Fremont-Smith a , Nicole Gherlone b , Nora Smith c , Philip Tisdall d , Darrell O. Ricke c , ∗ a Frank H Netter MD School of Medicine – Quinnipiac University, USA b AMITA Health Saint Joseph Hospital Chicago, Chicago, IL 60657, USA c Massachusetts Institute of Technology, Lincoln Laboratory, Lexington, MA, 02420, USA d Medical School Companion LLC, FL, USA a r t i c l e i n f o Article history: Received 16 June 2021 Revised 1 September 2021 Accepted 22 September 2021
https://www.ijidonline.com/article/S1201-9712%2821%2900763-3/pdf
2021 (06)
PIIS1201971221007633.pdf
ArticlePDF Available
Medical Countermeasures Analysis of 2019-nCoV and Vaccine Risks for Antibody-Dependent Enhancement (ADE)
January 2020
Authors:
RW Malone MD LLC
Download full-text PDFRead full-text
2023-04-13-researchgate-net-capture-340149846-medical-countermeasures-analysis-2019-ncov-and-vaccine-risks-for-antibody-dependent-enhancement-ade-img-1.jpg
2023-04-13-researchgate-net-capture-340149846-medical-countermeasures-analysis-2019-ncov-and-vaccine-risks-for-antibody-dependent-enhancement-ade.pdf
preprints202003-0138-v1x.pdf
THIS document is actually marked as March 8 2020 as last edit time ....
2023-04-15_20-44-18.jpg
SSRN.COm - Date is Mar 3 2020
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3546070
2023-04-15_20-39-37.jpg
2020 - March 03 - The Lancet (preprint) - "Medical Countermeasures Analysis of 2019-nCoV and Vaccine Risks for Antibody-Dependent Enhancement (ADE)"
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3546070
2020-03-03-papers-ssrn-com-sol3-papers-abstract-id-3546070.pdf
2020-03-03-papers-ssrn-com-sol3-papers-abstract-id-3546070-img-1.jpg
PDF paper : SSRN-id3546070.pdf
SSRN-id3546070-img-file-properties-hl-dates.jpg
DATA referenced ... https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/XWVOA8
Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
26 Pages Posted: 3 Mar 2020
Massachusetts Institute of Technology (MIT) - Lincoln Laboratory
Alchem Laboratories
Abstract
Background: In 80% of patients, COVID-19 presents as mild disease. 20% of cases develop severe (13%) or critical (6%) illness. More severe forms of COVID-19 present as clinical severe acute respiratory syndrome, T-predominant lymphopenia, high circulating levels of proinflammatory cytokines and chemokines, accumulation of macrophages and neutrophils in lungs, and immune dysregulation including immunosuppression.
Methods: All major SARS-CoV-2 proteins were characterized using an amino acid residue variation analysis method. Results predict that most SARS-CoV-2 proteins are evolutionary constrained, with the exception of the spike (S) protein extended outer surface. Results were interpreted based on known SARS-like coronavirus virology and pathophysiology, with a focus on medical countermeasure development implications.
Findings: Antibodies to variable S domains may enable an alternative infection pathway via Fc receptor-mediated uptake. This may be a gating event for the immune response dysregulation observed in more severe COVID-19 disease. Prior studies involving vaccine candidates for FCoV SARS-CoV-1 and Middle East Respiratory Syndrome coronavirus (MERS-CoV) demonstrate vaccination-induced antibody-dependent enhancement of disease (ADE), including infection of phagocytic antigen presenting cells (APC). T effector cells are believed to play an important role in controlling coronavirus infection; pan-T depletion is present in severe COVID-19 disease and may be accelerated by APC infection. Sequence and structural conservation of S suggests that SARS and MERS vaccine ADE risks may foreshadow SARS-CoV-2 vaccine risks. Autophagy inhibitors may reduce APC infection and T-cell depletion. Amino acid residue variation analysis identifies multiple constrained domains suitable as T cell vaccine targets. Evolutionary constraints on antiviral drug targets present in SARS-CoV-1 and SARS-CoV-2 may reduce risk of developing antiviral drug escape mutants.
Interpretation: Safety testing of COVID-19 S protein-based B cell vaccines in animal models is strongly encouraged prior to clinical trials to reduce risk of ADE upon virus exposure.
Funding Statement: U.S. Air Force Contract No. FA8702-15-D-0001.
Declaration of Interests: Dr. Ricke and Dr. Malone have nothing to disclose.
Ethics Approval Statement: Missing.
